Zydus’ generic of hormone therapy patch gets U.S. FDA nod
The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S. Federal Food, Drug, and Cosmetic Act.
· 10/21/2026, 12:28:44 PM· 2 min read
The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S. Federal Food, Drug, and Cosmetic Act.
Read original story →Related stories
business
NVIDIA targets 14-day AI data centre deployment with modular system
business
Civil servant denies 'criminal intent' after juggling five government jobs
business
Rupee closes at six-week high of 94.43 driven by Jio IPO, RBI intervention
business